COVID19 Infection in A Patient Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
Background: In the recent COVID19 pandemic, patients with hematological malignancies were considered high risk for severe disease. Limited data is available regarding course of COVID19 infection in this subgroup.
Case Presentation: We describe a case of 32-year‐old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection.
Conclusion: This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.
Figure 1
Posted 29 Sep, 2020
Invitations sent on 08 Nov, 2020
On 24 Sep, 2020
On 24 Sep, 2020
On 23 Sep, 2020
On 23 Sep, 2020
COVID19 Infection in A Patient Undergoing Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
Posted 29 Sep, 2020
Invitations sent on 08 Nov, 2020
On 24 Sep, 2020
On 24 Sep, 2020
On 23 Sep, 2020
On 23 Sep, 2020
Background: In the recent COVID19 pandemic, patients with hematological malignancies were considered high risk for severe disease. Limited data is available regarding course of COVID19 infection in this subgroup.
Case Presentation: We describe a case of 32-year‐old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection.
Conclusion: This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.
Figure 1